Since the ADJUVANT study first confirmed the significant prognostic benefit of EGFR-TKI application in postoperative EGFR-positive NSCLC patients (34), multiple subsequent clinical studies have similarly affirmed the positive impact of EGFR-TKIs on patient prognosis, significantly extending both DFS and OS compared to traditional chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.